Stocktoria
Outlook Therapeutics, Inc. OTLK
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2016-06-13
Outlook Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.4M | — | — | — | — |
| Gross profit | $57,205 | — | — | — | — |
| R&D expense | $27.2M | $41.8M | $26.5M | $42.3M | $39.0M |
| SG&A expense | $39.9M | $29.9M | — | — | — |
| Operating income | -$67.1M | -$71.7M | -$53.1M | -$63.1M | -$51.7M |
| Income tax | -$1.6M | $2,800 | $2,800 | $2,800 | $2,000 |
| Net income | -$62.4M | -$75.4M | -$59.0M | -$66.1M | -$53.2M |
| EPS (diluted) | $-1.79 | $-4.06 | $-4.72 | $-0.31 | $-0.35 |
| Operating cash flow | -$51.8M | -$68.8M | -$43.0M | -$56.7M | -$54.3M |
| Cash & equivalents | $8.1M | $14.9M | $23.4M | $17.4M | $14.5M |
| Inventory | $3.3M | — | — | — | — |
| Total assets | $18.6M | $28.8M | $32.3M | $28.5M | $22.8M |
| Total liabilities | $50.8M | $101.9M | $46.7M | $19.8M | $18.2M |
| Shareholders' equity | -$32.2M | -$73.1M | -$14.4M | $8.7M | $4.6M |
Source: SEC EDGAR filings · CIK 0001649989 · as of 2025-09-30. Facts from filings plus Stocktoria's own computed scores — not investment advice.